PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma

BACKGROUND: The treatment for advanced primary hepatocellular carcinoma (HCC) is sorafenib (SORA), while HCC has become increasingly drug resistant with enhanced aerobic glycolysis. The present study aimed to examine the chemotherapeutic effects of a flavonoid proanthocyanidin B2 (PB2) on HCC. METHO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Feng, Jiao, Wu, Liwei, Ji, Jie, Chen, Kan, Yu, Qiang, Zhang, Jie, Chen, Jiaojiao, Mao, Yuqing, Wang, Fan, Dai, Weiqi, Xu, Ling, Wu, Jianye, Guo, Chuanyong
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6525465/
https://ncbi.nlm.nih.gov/pubmed/31101057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1194-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados